IFNG and neoplasm: Other biomarkers, such as the tumour mutational burden (TMB), interferon-gamma signatures and tumour-infiltrating lymphocytes (TILS), among others, are biologically plausible but have yet to show a conclusive correlation with clinical outcomes.